Clinical trials: Rivaroxaban
Anticoagulant Adverse Reaction
Precision Medicine Platform for Novel Oral Anticoagulants
The anticoagulants have been developed with new generation for FDA-approved indications including treatment and prevention of venous, pulmonary, and systemic thromboembolism.
- Trial name
- NCT04056143
- Testing
- Pharmacogenomics
- Where
- Taiwan
- Volunteers
- 500 people
- Sponsor
- Kaohsiung Medical University
Non-valvular Atrial Fibrillation
A Nationwide Observational Study Looking at Effectiveness and Bleeding Complications of NOACs vs. VKA in Non-valvular Atrial Fibrillation Patients.
Using mandatory nationwide registries and possibly hospital electronic medical records in Norway, the researchers want to understand how well a group of drugs called "non-vitamin K antagonist oral anticoagulants" (rivaroxaban …
- Trial name
- PROTECT-AF (NCT03715725)
- Testing
- Rivaroxaban (Xarelto, BAY59-7939), Apixaban (Eliquis), Dabigatran etexilate (Pradaxa)
- Where
- Norway
- Volunteers
- 70,000 people
- Sponsor
- Bayer
Venous Thrombosis, Pulmonary Embolism
Study of Rivaroxaban Use and Potential Adverse Outcomes in Routine Clinical Pratice (UK)
This prospective cohort study will provide information about: characteristics of Rivaroxaban use in patients who are prescribed Rivaroxaban for the first time compared to patients who are prescribed Warfarin for the first time…
- Conditions
- Venous Thrombosis, Pulmonary Embolism, Atrial Fibrillation, Acute Coronary Syndrome
- Trial name
- NCT01947998
- Testing
- Rivaroxaban (Xarelto, Bay59-7939), Warfarin, Antiplatelet drugs
- Where
- United Kingdom
- Volunteers
- 50,299 people
- Sponsor
- Bayer
Venous Thromboembolism
Comparison of Oral Anticoagulants for Extended VEnous Thromboembolism
Comparison of Oral anticoagulants (warfarin, apixaban and rivaroxaban) for extended VEnous Thromboembolism.
- Trial name
- COVET (NCT03196349)
- Testing
- Warfarin, Apixaban 2.5 MG, Rivaroxaban 10 MG
- Where
- United States
- Volunteers
- 44 people
- Sponsor
- Duke University
Ischemic Stroke, Atrial Fibrillation
Single-stage Pulmonary Vein Isolation Combined With Percutaneous Left Atrial Appendage Occluder Implantation in Patients With Recent Onset Ischemic Stroke and Atrial Fibrillation
The project is a multicenter, open-label, randomized medical experiment, which was designed to evaluate the efficacy and safety of single-stage pulmonary vein isolation (PVI) and implantation of left atrial appendage occluder…
- Trial name
- PILOS-AF (NCT06212674)
- Testing
- PVI + LAAO, single stage, LAAO, NOAC
- Where
- 2 sites in Poland
- Volunteers
- 240 people
- Sponsor
- Medical University of Silesia
Thromboembolism
Rivaroxaban for Treatment in Venous or Arterial Thrombosis in Neonates
The purpose of this study is to find out whether rivaroxaban is safe and effective to use in children age newborn to less than 6 months and how long it stays in the body and how it is used in the body.
- Trial name
- Einstein Jr (NCT02564718)
- Testing
- Rivaroxaban (Xarelto, BAY59-7939)
- Where
- 9 sites in Austria, France and 5 more
- Volunteers
- 10 people
- Sponsor
- Bayer
Antiphospholipid Syndrome
Telitacicept Followed With Rituximab Therapy on APS Secondary to SLE
The aim of this study was to observe the clinical efficacy and safety of rituximab (RTX) combination with telitacicept (TA) in patients of systemic lupus erythematosus secondary antiphospholipid syndrome (APS).
- Trial name
- NCT05644210
- Testing
- Telitacicept, Rituximab, Aspirin
- Where
- China
- Volunteers
- 80 people
- Sponsor
- Qilu Hospital of Shandong University
Brain Ischemia
Xarelto [SPAF] Post-marketing Surveillance in Japan
This study is a regulatory post-marketing surveillance in Japan, and it is a local prospective and observational study of patients who have received Xarelto for SPAF.
- Trial name
- NCT01582737
- Testing
- Rivaroxaban(Xarelto, BAY59-7939)
- Where
- Japan
- Volunteers
- 11,310 people
- Sponsor
- Bayer
Genital Haemorrhage
Genital Haemorrhage in Woman of Childbearing Age Treated for Venous Thromboembolism Disease : Comparison According to Oral Anticoagulant and Impact on Quality of Life
Little data are available on the genital haemorrhages in woman of childbearing age treated for venous thromboembolic disease by oral anticoagulant, especially the impact on the quality of life.
- Trial name
- GENB-OAB (NCT03772366)
- Where
- France
- Volunteers
- 453 people
- Sponsor
- Assistance Publique Hopitaux De Marseille
ST Segment Elevation Myocardial Infarction, Left Ventricular Thrombus
Treatment of Post-STEMI Left Ventricular Thrombus With Optimized Anticoagulant
Left ventricular thrombus is a common complication subsequent to ST-segment elevation myocardial infarction (STEMI) that related to increased embolic events.
- Trial name
- EARLYmyo-LVT (NCT03764241)
- Testing
- Rivaroxaban, Vitamin K Antagonist
- Where
- China
- Volunteers
- 280 people
- Sponsor
- RenJi Hospital
Coagulation Disorder
Single Dose Trial of VMX-C001 in Healthy Subjects With and Without FXa Direct Oral Anticoagulant
A single centre, double-blind, randomized, placebo-controlled single dose study to assess the safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of VMX-C001, conducted in two parts: Part 1: Single dose of…
- Trial name
- NCT06372483
- Testing
- VMX-C001, Rivaroxaban 20 mg Oral Tablet, Apixaban 5 mg Oral Tablet
- Where
- Netherlands
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- VarmX B.V.
Ischem Heart Disease, Primary Coronay Intervention
CHAOS Registry Study
INTRODUCTION: About 6-8% of patients undergoing PCI have an indication for long-term oral anticoagulants (OACs) due to various conditions such as atrial fibrillation (AF), mechanical heart valves, or venous thromboembolism.
- Conditions
- Ischem Heart Disease, Primary Coronay Intervention, Oral Anticoagulants, Atrial Fibrillation
- Trial name
- CHAOS (NCT03558295)
- Testing
- Oral Anticoagulant
- Where
- Italy
- Volunteers
- 1,000 people
- Sponsor
- A.O.U. Città della Salute e della Scienza
Thromboses, Deep Vein, Surgery--Complications
Thromboprophylaxis in Patients Undergoing Orthopedic Surgeries; Comparison Between Rivaroxaban and Enoxaparin
The main objective is to reduce the incidence of venous thromboembolism (VTE) in orthopedic postoperative patients based on the potential benefit of using rivaroxaban as a monotherapy.
- Trial name
- NCT03299296
- Testing
- Rivaroxaban 10 Milligrams, Enoxaparin 40 Milligrams/0.4 Milliliters Prefilled Syringe
- Volunteers
- 100 people
- Sponsor
- Ahmed AbdelMoneim Hassan Ali
Atherosclerosis, Coronary
Effects of Rivaroxaban on Vascular FMD in Patients With Stable Atherosclerotic Vascular Diseases
The specific mechanistic benefit of rivaroxaban versus other FXa inhibitors on atherothrombotic events remain unclear. Therefore plan to initiate a prospective, randomized study to investigate the effect of rivaroxaban and…
- Trial name
- NCT06986369
- Testing
- Rivaroxaban 2.5 MG Oral Tablet [Xarelto]
- Where
- China
- Volunteers
- 140 people
- Sponsor
- The University of Hong Kong
Arthritis, Osteoarthritis, Knee
Switching Drug Therapy for the Prevention of Blood Clot Formation From Enoxaparin to Rivaroxaban After Orthopedic Surgery for Either Total Hip or Total Knee Replacement
The study will describe the short-term effects the study drug, rivaroxaban, has on the body when a patient is switched from enoxaparin injection (by needle) to oral rivaroxaban (by mouth) for the prevention of blood clotting in…
- Conditions
- Arthritis, Osteoarthritis, Knee, Osteoarthritis, Hip, Thromboembolism
- Trial name
- NCT01094886
- Testing
- Rivaroxaban
- Where
- 5 sites in United States
- Volunteers
- 56 people
- Sponsor
- Ortho-McNeil Janssen Scientific Affairs, LLC
Left Ventricular Thrombus
LVT DURATION: Pilot Study of Anticoagulation Duration for Left Ventricular Thrombus
The LVT DURATION (Optimal Duration of Anticoagulation for LV Thrombus) is a pilot study planned to assess the practicalities of conducting a randomised control trial (RCT) whilst establishing data around the ideal duration of…
- Trial name
- LVT Duration (NCT07246005)
- Testing
- Continue rivaroxaban or apixaban or warfarin, Discontinue rivaroxaban or apixaban or warfarin
- Where
- United Kingdom
- Volunteers
- 120 people
- Sponsor
- Queen Mary University of London
Relapsed/Refractory Multiple Myeloma (RRMM), Multiple Myeloma
Epunamin Combined With DECP for Relapsed/Refractory Multiple Myeloma
Background: Multiple Myeloma remains an incurable hematologic malignancy, and outcomes for relapsed/refractory multiple myeloma (RRMM) remain unsatisfactory despite advances in therapy.
- Trial name
- NCT07497165
- Where
- China
- Volunteers
- 48 people
- Sponsor
- Shanxi Bethune Hospital
Left Atrial Appendage Thrombosis, Thrombi
Clinical Outcomes Between Anticoagulation and DAPT Therapy in AF Patients Successfully Undergoing LAAO
The objective of this study is to assess the efficacy and safety different dosage of rivaroxaban application versus dual antiplatelet therapy after successful closure of left atrial appendage using the LAMBRE device.
- Conditions
- Left Atrial Appendage Thrombosis, Thrombi, Stroke
- Trial name
- NCT04135677
- Testing
- Rivaroxaban, DAPT
- Where
- China
- Volunteers
- 826 people
- Sponsor
- Shanghai Zhongshan Hospital
Acute Coronary Syndrome, Myocardial Infarction
An Efficacy and Safety Study for Rivaroxaban in Patients With Acute Coronary Syndrome
The purpose of this study is to determine whether rivaroxaban in addition to standard care reduces the risk of the composite of cardiovascular death, myocardial infarction, or stroke in patients with a recent acute coronary…
- Conditions
- Acute Coronary Syndrome, Myocardial Infarction, Myocardial Ischemia, Unstable Angina
- Trial name
- NCT00809965
- Testing
- Rivaroxaban 2.5 mg, Rivaroxaban 5 mg, Standard of care
- Where
- 556 sites in United States, Argentina and 41 more
- Volunteers
- 15,526 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Valvular Heart Disease
RIvaroxaban for Valvular Heart diseasE and atRial Fibrillation Trial -RIVER Trial
RIvaroxaban for Valvular heart diseasE and atRial fibrillation trial (RIVER trial).
- Trial name
- NCT02303795
- Testing
- Rivaroxaban, Warfarin
- Where
- Brazil
- Volunteers
- 1,005 people
- Sponsor
- Hospital do Coracao